~" Currently available diagnostic tracers for brain tumors are not specific. Tumorspecific tracers would improve the detection of brain tumors by gamma encephalograpby. Glucose is an important substrate for tumor metabolism and is known to be taken up in large amounts. The authors have studied five labeled carbohydrates in an attempt to find a tumor-specific tracer: three were tritiated (L-galactose-l-3H, Lfucose-3H, and 4,6-dideoxy-xylo-hexose-aH) and two were radioiodinated (methyl-6-l~sI-6-deoxy-D-glucoside and 6-125I-6-deoxy-D-glucose). The uptake of these tracers by a transplantable mouse ependymoblastoma after intravenous injection was determined by liquid and well scintillation counting. The highest tumor-to-brain ratio was 7.1 to 1 for the tritiated tracers and 6.2 to 1 for the radioiodinated tracers. Although these ratios are not high enough for gamma encephalography, one of the iodinated tracers may be useful for enhancement of contrast in computerized axial tomography.
D
URING the past 25 years the detection of brain tumors with radioisotopes has become one of the most valuable tests in clinical neurology and neurosurgery. Although new tracers and detection apparatus have been introduced during the past decade, the detection rate for brain tumors has remained about 80%. 5'12 All tracers in use at the present time depend upon exclusion from brain to yield tumor-to-brain differences of sufficient magnitude to permit detection of tumors by isotopic encephalography. Indeed, the fact that different tracers give similar tumor-to-brain ratios has led some investigators to conclude that many of these remain extracellular and produce uptake ratios which are proportional to the extracellular spaces of tumor and brain, that is, about 15:1.1~ Improved tumor-to-brain ratios and better detection rates would result from the discovery of tumor-specific tracers.
High intracellular uptake by neoplastic cells and a tumor concentration of the labeled material in excess of the concentration initially present in blood are essential characteristics of a highly specific diagnostic tracer for gamma encephalography. None of the currently used tracers, such as pertechnetate99mTc, is tumor specific according to these criteria. Indeed, of the 19 tracers studied in this laboratory, none was concentrated in tumor to a greater degree than that found in one or more normal tissues such as liver, kidney, or stomach. 14 It was felt that carbohydrate analogues might be useful as tumor-specific tracers since carbohydrates are in high demand by tumor for energy and growth. 11 The uptake of glucose and glucose analogues, such as 3-0-methyl-D-glucose, 2-deoxy-D-glucose, and 2-chloro-2-deoxy-D-glucose have already been examined in this laboratory." The high tumor uptake attained by these tracers, especially 2-deoxy-D-glucose and 2-chloro-2-deoxy-Dglucose, prompted the present study of other carbohydrates including L-galactose-l-3H, Lfucose-3H (6-deoxy-L-galactose), and 4,6-dideoxy-xylo-hexose-3H. In addition, two iodinated glucose derivatives, methyl-6-125I-6 -deoxy-D-glucoside and 6-125I-6-deoxy-Dglucose were also investigated. Radioiodinated (131I) glucose derivatives could be used clinically for cerebral scintigraphy if their biological properties proved favorable.
Materials

Tumor
We used C57BL/6J female mice* 4 to 6 weeks of age weighing 16 to 18 gm. The tumor was a mouse ependymoblastoma that has been maintained in our laboratory for the past 11 years by serial subcutaneous transplantation of tumor fragments every 2 weeks into the lower abdominal wall. The tumor was originally induced by Zimmerman and Arnold 19 in mouse brain with intracerebrally implanted methylcholanthrene.
Tracers
The tracers included L-fucose-ZH, 4.8 Ci/mmol, L-galactose-l-aH, 22.8 Ci/mmol,~-and 4,6-dideoxy-xylo-hexose.8:~ The latter substance was demethylated 8 and placed on a silica gel chromatography platew that was plated on both sides with a nonradioactive 4,6-dideoxy-xylo-hexose standard. Development was achieved with chloroform:meth-*C57BL/6J mice were obtained from Jackson Laboratory, Bar Harbor, Maine.
tL-fucose-SH was obtained from New England Nuclear Corporation, Boston, Massachusetts; Lgalactose-l-aH was purchased from AmershamSearle Corporation, Toronto, Canada.
:~4,6-dideoxy-xylo-hexose was the gift of Dr. J.K.N. Jones, Queens University, Kingston, Ontario, Canada. This substance in the form of a methyl glycoside was sent to New England Nuclear Corporation, Boston, Massachusetts, for tritium exposure by the Wilzbach technique. w gel chromatography plate (DC-Fertigplatten Sil G) manufactured by Macherey-Nagel and Company, Duren, Germany. anol 9: 1. The center of the chromatographic plate was covered with a piece of glass leaving only the nonradioactive standards exposed. The standards were detected by spraying with concentrated sulphuric acid and heating with a small flame applied directly to the sprayed areas. The silica gel between the two spots of the nonradioactive 4,6-dideoxy-xylo-hexose standard was scraped off the plate and eluted with methanol. The purity of this fraction was determined by spotting an aliquot on a silica gel instant thin layer chromatograph,** which was then developed in chloroform:methanol 9:1, cut into 0.5-cm sections, placed in vials containing scintillation fluid,tt and counted in a liquid scintillation counter.~:~ The results showed that 98% of the radioactivity moved with the 4,6-dideoxyxylo-hexose standard. The amount of hexose in an aliquot was determined by means of the phenol-sulphuric acid colorimetric method e and the specific activity was calculated to be 0.02 Ci/mmol.
The 6-iodo derivatives were made in our laboratory. Methyl-6-I-6-deoxy-D-glucoside was initially prepared as described by Raymond and Schroeder. 13 The radioactive material was prepared from a precursor, methyl-6-0-p-tosylsulfonyl-ot-D-glucopyranoside, prepared according to a method described by Cramer: 1 50 mg of methyl-6-0-ptosylsulfonyl-a-D-glucopyranoside, 2 ml of acetone, and 1 mCi of Na126Iw167 at a specific activity 17 Ci/mg were put into a 10-ml pressure vessel and heated in a boiling water bath for 4 hours. The reaction products and a standard of methyl-6-I-c~-D-glucoside were placed on silica gel and developed with a mixture of chloroform: methanol 3:1. The standard was detected as described above for 4,6-dideoxy-xylo-hexose and the methyl-6-12%6-deoxy-D-glucoside eluted from the silica **Instant thin layer chromatograph type chromatography media were manufactured by Gelman Instrument Company, Ann Arbor, Michigan.
ttOxifluor-H20, was obtained from New England Nuclear Corporation, Boston, Massachusetts.
:~Unilux II liquid scintillation counter manufactured by Nuclear-Chicago, 2954 Peachtree Road, N.E., Atlanta, Georgia 30319. w167 was obtained from Atomic Energy of Canada Limited, Commercial Products Division, Ottawa, Canada. gel with ethanol. An aliquot of methyl-6-~2~I-6 -deoxy-D-glucoside was rechromatographed and this showed that 98% of the radioactivity moved with the nonradioactive methyl-6-I-6-deoxy-D-glucoside standard.
For the production of 6-'2~I-6-deoxy-D-glucose, 6-~q-6-deoxy-D-glucoside was dissolved in 2 ml of water in a 10-ml pressure vessel, to which was added 250 mg of Rexyn 101 (+H) resin.* The pressure vessel and contents were kept in a boiling water bath for 7 hours. The reaction products were plated out on silica gel and developed with chloroform: methanol 3: 1. Three radioactive spots were detected, one of which coincided with NaI standard (25% of radioactivity) and a second which coincided with the starting material methyl-6-n~I-6-deoxy-D-glucoside (25% of the radioactivity). Between these two zones of radioactivity was a third zone which contained 50% of the total substance as determined by the ferricyanide test) It was concluded that this substance was 6-~I-6-deoxy -D-glucose. Radiochemical purification of 6-1~5I-6-deoxy-D-glucose was done on silica gel and a repeat chromatogram showed that 95% of the radioactivity moved with the nonradioactive 6-I-6-deoxy-D-glucose standard and 4% with the NaI standard. The specific activity of the radioiodinated sugars was calculated from the specific activity of the original 1~5I and was approximately 21 mCi/mg of sugar.
Tritiated materials were prepared for injection by first evaporating off the solvents in which they were stored and then dissolving the residue in 0.90% saline so that a concentration of 100 /~Ci/ ml was obtained. Each mouse received 1 uCi in 0.01 ml solution intravenously per gram body weight. Methyt-6-~2~I-6-deoxy-D-glucoside and 6-1~I-6-deoxy -D-glucose were similarly prepared except that the injected solution contained 50 ~tCi/ml and each mouse received 0.5 uCi in 0.01 ml solution intravenously per gram body weight.
Methods
Experimental Protocol
Mice bearing 14-to 18-day-old subcutaneous tumors were deprived of food but not water for 4 hours prior to the administra-*Rexyn 101 (+H) resin obtained from Fisher Scientific Company, Toronto, Canada. tion of the tracers so that blood glucose values would tend to be uniform. After intravenous administration of the tracers to separate groups, the mice were sacrificed at selected time intervals from 2 minutes to 24 hours. Each time at least six mice were sacrificed by decapitation and a terminal arterial blood sample was collected. Samples of brain, subcutaneous tumor, muscle, blood, liver, and kidney were taken for radioisotopic assay. L-galactose-l-SH and methyl-6-12~I-6-deoxy-D-glucoside were studied at 2 and 10 minutes, and 1 and 2 hours; 4,6-dideoxy-xylo-hexose-3H and L-fucose-3H were studied at 2 and 10 minutes, and 1, 2, and 24 hours; 6-:~I-6-deoxy-D-glucose was studied at 2 and 10 minutes, and 1, 2, and 24 hours; and 6-12~I-6-deoxy-D-glucose was studied at 2, 10, and 30 minutes, and 2, 4, and 6 hours after injection.
Sample Preparation
Tritium containing solid tissue samples ranging in weight from 50 to 200 mg were placed in ashless filter paper baskets made from 2.1 cm diameter Whatman 0.541 filter paper circles. The baskets were in preweighed vials which were then reweighed. To avoid evaporation, the samples were kept in the vials until just before combustion, at which time they were removed from the vials, rolled in 9.0-cm circle Whatman No. 42 ashless filter paper, and compressed into pelletst to ensure uniformity of burning and maximum recovery. At the time of sacrifice, blood samples were placed directly on filter paper pellets made as above, and the blood weight was determined in a manner similar to that for the other tissues. The samples were placed in a sample oxidizer where combustion occurred.$ 7
Tritiated water was collected in a vial of scintillation cocktail composed of naphthalene 100.0 gm, PPO (2, 5-diphenyloxazole) 5.0 gm, dimethyl POPOP (1,_ 4-bis [2-(4-methyl-5-phenyloxazolyl)]) benzene 0.3 gm, dioxane 720 ml, toluene 135 ml, and absolute methanol 45 ml. This cocktail gave a counting efficiency of 24% to 28%. The recovery eftPellet Press, Parr Instrument Company, Moline, Illinois.
SPackard-Kinaarten Model 305 sample oxidizer made by Packard Instrument Co., Inc., Downers Grove, Illinois.
Carbohvdrates as diagnostic tracers for brain tumors Fro. 1. Log-log plot showing L-fucose-3H distribution. Each point is the average of at least six tissues.
The molecular structure is depicted in the left-hand corner.
ficiency of the automated combustion technique was determined at regular intervals. A standard solution was made with 20 uCi of radioactive tracer in 100 ml of water, from which 0.1 ml aliquots were pipetted into each of the three vials filled with scintillation fluid and onto each of five filter paper pellets. The filter paper pellets were then combusted and the radioactive products collected in the usual manner. The radioactivity recovered from the combusted pellets was then compared with that placed directly into the scintillation fluid, and the recovery was found to be about 92% to 96%. There was a carry-over of radioactivity from one combusted sample to the next of about 2%. To prevent this a blank filter paper pellet was combusted between each radioactive tissue sample. The radioactive tracer standards were counted together with the tissue samples at 4 ~ C in a Unilux II liquid scintillation counter with the channels ratio method. A minimum of 10,000 counts was recorded for each sample. For l*5I-labeled tracers, solid tissue samples weighing 50 to 200 mg or 0.1 ml blood were placed in pre-weighed vials, reweighed to determine tissue weight, and then potassium hydroxide 5N was added to each vial to digest the tissue and to adjust the volume to 2 ml. The samples were left overnight at room temperature for digestion before counting. A standard solution of radioiodinated tracer was made in a manner similar to that for the all-labeled tracers, by placing a 0.l-ml aliquot of the tracer into each of the three counting vials, and adjusting the volume to 2 ml with potassium hydroxide 5N. The samples and the standards were then counted together in a Philips well scintillation counter.
Calculations
The uptake of radioactivity in the tissues is expressed as the percentage dose. This value is a ratio of the disintegrations per second and not excreted is 100% in all tissues. To determine the DPS or DPM injected/gm animal an aliquot of the injected tracer was counted along with the tissue samples. Calculations were done on a Sigma-5 computer by the Medical Computing Department at the University of Toronto.
Results
With L-fucose-3H tumor uptake was 55 + 23% dose at 2 minutes, constant for the next 2 hours, and by 24 hours following injection it had dropped to 37.0 + 9.6% (Fig. 1) . Brain uptake also remained almost constant over the 24-hour period, being 9.3 + 1.3% at 2 minutes and 12.3 4-4.8% at 24 hours. Intestine had an uptake of 148 + 26%. The highest uptake was found in kidney which had an initial value of 690 + 180%, and 24 hours later the value was still high at 220 + 25%.
With L-galactose-l-SH radioactivity at 2 minutes was at a maximum in all tissues except tumor, where the maximum uptake of 65.1 + 5.0% dose was not reached until 10 minutes after injection (Fig. 2) . At 2 hours, tumor uptake had diminished to 22.1 + 3.4%.
Fie. 3. Log-log plot showing the distribution of 4,6-dideoxy-xylo-hexose-3H. Each point is an average of at least six tissues. The molecular structure is depicted in the left-hand corner.
Brain uptake started low at 12.5 + 3.0% and remained lcw over the 2-hour period. Kidney was the most radioactive of all tissues at all three time intervals. The distribution of 4,6-dideoxy-xylohexose-3H is shown in Fig. 3 . At 2 minutes, tumor had the lowest radioactivity of all tissues, 24 • 12% dose, but by 10 minutes it had increased to 50 + 12%. At 2 minutes, brain was the second lowest radioactive tissue at 43 + 13%, and from 10 minutes to 1 hour, brain was the least radioactive tissue.
Tissue radioactivity after methyl-6-12q-6-deoxy-D-glucoside injection is shown in Fig.  4 . At 2 minutes, tumor was 32 -4-15% dose, and by 10 minutes it had doubled to 66.6 + 9.5%. At 30 minutes it peaked at 84.4 4-2.7%, but by 2 hours it had declined to 36.1 + 6.9%. Brain started much lower at 9.9 + 0.8%, but by 30 minutes had tripled to 32.9 + 3.6% and then remained at this level for the next 1.5 hours. Figure 5 shows the distribution of 6-155I-6 -deoxy-D-glucose. Tumor uptake began at 29.6 + 6.7% dose, by 10 minutes it had reached 71 + 28% and at 2 hours it was still high at 68.7 + 4.8%, after which it slowly declined to 52.5 • 9.1% at 6 hours. Brain uptake was initially 44.1 + 5.0%, rose to 64.4 4-4.1% at 10 minutes, and then dropped to 8.5 + 0.7% at 6 hours. Blood was the most radioactive of all tissues over the 6-hour period.
Fro. 4. Log-log plot showing methyl-6-1~sI-6 -deoxy-D-glucoside distribution, above. Each point is the average of at least six tissues. The molecular structure is depicted in the left-hand corner.
Discussion
All tracers in current clinical use for brain tumor detection are nonspecific and depend upon an intact blood-brain barrier for differences in lesion-to-brain uptake. Improvement in the detection rate of brain tumors would occur if a tumor-specifc tracer was discovered. Ideally, such a tracer would have an extremely high concentration in brain tumors, a high tumor-to-brain concentration ratio, and a low concentration in brain, blood, scalp, bone, and muscle. Elevated activity levels in these "background" tissues interfere with the detection of tumors, especially in areas covered by muscle and near large venous channels.
In the past there have been other attempts to find tumor-specific tracers by using labeled substances required by the tumor as substrates for tumor metabolism, 2,~ but there have been no previous attempts to use labeled FI6. 5. Log-log plot showing the distribution of 6-125I-6-deoxy-D-glucose. The molecular structure is depicted in the left-hand corner. Each point is the average of six uptake values except for the 6-hour time interval when only three animals were studied.
carbohydrates for this purpose. Over half a century ago Warburg observed that tumors had a high rate of aerobic and anaerobic glycolysis. ~8 It has been shown repeatedly since then that tumors have a high glucose uptake, TM and thus it was felt that glucose analogues might be avidly accumulated by neoplastic cells. Weinhouse is recently discussed the high rates of aerobic glucose metabolism seen in certain experimental tumors and suggested that the increased rate of glucose metabolism was due to a shift in glycolytic enzymes toward enzymes which were less responsive to host controls. It was felt that these enzymes might also respond to glucose analogues at rates different from normal tissue, thus providing a clinically exploitable difference. Another possible advantage of a glucose analogue as a tracer for brain tumor detection is that the analogue might be rapidly metabolized resulting in a high rate of blood clearance. This would produce lower levels of radioactivity in the "background" tissues including the dural venous sinuses, temporalis muscles, and scalp.
L-fucose (6-deoxy-L-galactose) has wide distribution in mammalian tissues in the form of glycoproteins, mucoproteins, and as a constituent of cell membranes. It was hoped that large amounts would be taken up by tumor due to L-fucose incorporation into the cell membrane during division and growth. For the same reasons, certain normal tissues such as intestinal mucosa that have high rates of cell turnover would also be expected to show an increasingly higher uptake with time. Unfortunately, tumor showed neither a very high initial uptake nor a significant increase with time ( Fig. 1) . In contrast, intestine showed a high initial uptake and an avid accumulation over the first hour of the study. Although blood radioactivity dropped from 222% to 77% dose at 1 hour, intestine increased its uptake from 148% to 226%. Unfortunately, neither the tumor radioactivity nor the tumor-to-brain ratio is high enough for clinical brain tumor detection.
In an attempt to improve the tumor-tobrain ratio L-galactose was studied because it is similar to L-fucose (6-deoxy-L-galactose) except that L-galactose has a hydroxyl group at carbon six. The tumor radioactivity with L-galactose at 10 minutes was significantly different from L-fucose, although there were no significant differences in brain radioactivity between the two tracers and the tumor-to-brain ratio of 7.1 to 1 was only slightly higher.
We chose 4, 6-dideoxy-xylo-hexose for the study because of the high tumor uptake achieved with another deoxy compound, namely, 2-deoxy-D-glucose. 17 The tumor uptake with 4,6-dideoxy-xylo-hexose-SH was, however, very low and the tumor-to-brain ratio was inadequate for scanning. The tissue distribution and elimination would indicate that this tracer is not metabolized and is rapidly excreted from the animal.
Methyl-6-125I-6-deoxy-D-glucoside is of particular interest because it could be easily labeled with the clinically useful tracer la'I. A short synthesis is described by Raymond and Schroeder, is who made this compound while searching for nontoxic, water-soluble, iodinated organic compounds for x-ray contrast agents in urography. Tumor and brain both showed a threefold rise over the first 30 minutes following injection. The uptake in tumor is probably due to passive diffusion since the tumor value increased as long as the blood uptake was higher than tumor uptake, but as soon as the blood uptake decreased to the maximum tumor value, blood and tumor uptake diminished together. The tracer uptake by tumor and brain over the first 30 minutes produced a constant tumor-to-brain ratio of only three which is not high enough for this agent to be considered as a potential scanning agent.
The tracer 6-125I-6-deoxy-D-glucose was chosen because it was felt this reducing sugar might demonstrate a more vigorous uptake by tumor than the methyl glucoside discussed above. Unfortunately, tumor uptake did not improve. Ten minutes after injection the tumor content doubled and remained approximately constant over the next 2 hours. Brain uptake also increased over the first 10 minutes but by 2 hours it was significantly below its initial value. The study was extended to 6 hours from the time of injection because if brain radioactivity had continued to decline and if tumor radioactivity had remained constant it might have been possible to attain high tumor-to-brain ratios. This expectation was only partially fulfilled because brain showed a 75% decrease while tumor showed only a 24% decrease as compared with the 2-hour values. In this time interval a * Maximum uptake values in tumor and brain, and maximum tumor-to-brain and brain-to-tumor ratios after intravenous administration of tracers to mice bearing the subcutaneous ependymoblastoma. Each value represents the mean results of six mice.
t Data from Schwartz and Tator. 14 brain-to-tumor ratio of 1.5 to I became a tumor-to-brain ratio of 6.2 to 1 (Table 1) . However, the uptake of only 52% dose in tumor was too low for detection by external scintiscanning and therefore the experiment was not extended further.
To evaluate the tracers studied here it is worthwhile to compare them with currently used tracers such as pertechnetate-99mTc, which was studied in the same mouse tumor model? 4 It can be seen from Table 1 that the maximum tumor-to-brain ratio attained in the present study was 7.1 which is only half the ratio achieved with pertechnetate-99mTc. In addition, the maximum tumor values are not significantly higher than those achieved with pertechnetate. Furthermore, the uptake values in tumor of the carbohydrate tracers investigated here fall short of those values found with the carbohydrates studied previously such as 2-deoxy-D-glucose and 2-chloro-2-deoxy-D-glucose? 7 Unfortunately, the tumor concentrations, tumor-to-brain ratios, brain concentrations, and brain-to-tumor ratios found in the present study are too low for radiosotopic encephalography. With the advent of computerized axial tomography, which measures fine gradations of tissue density, nonradioactive, iodinated carbohydrates might be a useful adjunct to the detection and delineation of brain tumors by this technique. For example, with 6-1~q-6-deoxy-D-glucose the concentration in tumor was six times larger than the concentration in brain 6 hours after intravenous injection (Table 1 ), The resultant difference in density might help to delineate tumor from normal brain on the tomograms. This approach is currently being used with the use of conventional contrast media such as Hypaque. Unfortunately, there has not been a study of the uptake of radioiodinated Hypaque by experimental brain tumors which might be compared with the results obtained here with the radioiodinated sugars. The only contrast agent which has been studied in this way is cholografin, which Long, et al., 1~ measured in a mouse brain tumor similar to the one used here. Their method of reporting data differs from ours in that their 1% of dose is equivalent to our 100% of dose. They found that the maximum uptake of cholografin was equivalent to our 20% of dose. In contrast, methyl-6-12q-6-deoxy-D-glucoside had a maximum tumor uptake of 84.4 + 2.7% of dose and 6-12q-6-deoxy-D-glucose had a maximum tumor uptake of 74.2 + 28% of dose. We feel the values for the sugars compared favorably to cholografin. However, if a radioiodinated sugar was selected for use in patients it would first be necessary to determine its possible toxicity.
It is acknowledged that if one of the tritiated carbohydrates had shown tumor specificity it would have been necessary to label it with a gamma-emitting isotope of suitable energy and half-life for the carbohydrate to be of clinical value. With the 12q_ labeled analogues, clinical application could have been accomplished by radioiodination with lSlI which can be used for radioisotopic encephalography. The introduction of other radioisotopes such as 'gF in place of 3H or 14C could significantly alter the uptake characteristics of these tracers. If the ideal carbohydrate tracer had been found, attempts at labeling with ~C would have been considered. Carbon-11 is a positron emitter which yields clinically useful gamma energies. This isotope has a half-life of only 20.8 minutes and therefore any synthesis carried out after its production must be rapid. However, it has been possible to make glucose-~aC biosynthetically 9 and to use this tracer for studying regional cerebral metabolism in patients.
